Optimizing LDL-C Management in the Post-MI Patient - a podcast by ReachMD

CME credits: 0.50

Valid until: 15-07-2022

Claim your CME credit at https://reachmd.com/programs/cme/optimizing-ldl-c-management-post-mi-patient/12664/

Cholesterol guidelines recommend nonstatin, LDL-C-lowering therapies in very high risk ASCVD patients if LDL-C goals are not achieved (ESC/EAS dyslipidemia guideline) or if LDL-C is above a specific threshold of 70 mg/dL (AHA/ACC cholesterol guideline). Unfortunately, a substantial number of patients with ASCVD do not achieve LDL-C targets, and nonstatin, LDL-C-lowering therapies are underutilized. Therefore, patients such as those who have experienced an acute coronary syndrome (ACS) remain at increased risk for another major cardiovascular event. Patients with a recent ACS are especially vulnerable to a recurrent cardiovascular event. Nonstatin, LDL-C-lowering therapy with PCSK9 inhibitors and ezetimibe has demonstrated reductions in cardiovascular risk after an ACS. PCSK9 inhibitors have demonstrated robust LDL-C lowering to very low LDL-C levels, with no increase in adverse safety events and with additional cardiovascular risk reduction. Analyses of cardiovascular outcome trial data with PCSK9 inhibition have indicated particularly potent cardiovascular risk reduction in patients with a recent ACS; utilizing PCSK9 inhibitors in these patients enables clinicians to greatly improve their patients’ clinical outcomes. Significant LDL-C reductions, rapid LDL-C goal attainment, and safety have been observed in very early (in-hospital) use of PCSK9 inhibitors. In this educational initiative, lipid expert Dr. Marc Sabatine will discuss guideline ...

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD